IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

Hima Patel(Kansas City University), Joan T. Garrett(University of Cincinnati Medical Center)

Cancers

November 22, 2021

10.3390/cancers13225863

Cited by 33

Related Papers

Current Advances in the Treatment of BRAF-Mutant Melanoma

|Cancers|2020|172

Activating HER3 mutations in breast cancer

|Oncotarget|2018|36

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers

|PLoS ONE|2023|9

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells

|Anti-Cancer Drugs|2023|6